Communiqués AstraZeneca PLC

Actions

AZN

GB0009895292

Produits pharmaceutiques

Marché Fermé - London S.E. 17:35:16 28/08/2026			Varia. 5j.	Varia. 1 janv.
11 970,00 ^GBX	-1,19 %		-2,21 %	-13,20 %

28/08	AstraZeneca PLC : Jefferies réitère son opinion positive sur le titre	ZD
28/08	AstraZeneca annonce des résultats de phase III positifs pour le Tezspire dans l'oesophagite à éosinophiles	CI

Communiqués

27/08	TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints	BU
20/08	Foresite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture Partner	AQ
18/08	AstraZeneca - Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer	AQ
17/08	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	BU
17/08	TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO	BU
17/08	HUTCHMED Announces ORPATHYS plus TAGRISSO Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer	AQ
17/08	AstraZeneca : Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	PU
17/08	AstraZeneca : Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer	PU
04/08	BITTER PILL TO SWALLOW?	AQ
27/07	Beyond De-risking: How European Companies Can Develop New Technologies In China	AQ
27/07	Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers	BU
27/07	AstraZeneca results: H1 and Q2 2026	BU
27/07	Astrazeneca: Q2 Earnings Snapshot	AQ
27/07	AstraZeneca : Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant	PU
27/07	AstraZeneca : Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant	PU
27/07	Half-year Financial Report	AQ
24/07	AstraZeneca : Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer	PU
24/07	AstraZeneca : Trixeo recommended for approval in the EU by CHMP for the maintenance treatment of asthma	PU
15/07	Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy	AQ
14/07	AstraZeneca : enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical	PU
29/06	AstraZeneca : Enhertu approved in EU for HER2+ solid tumours	PU
29/06	AstraZeneca : Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours	PU
29/06	AstraZeneca : Datroway recommended for approval in EU for TNBC	PU
28/06	AstraZeneca : Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve paediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial	PU
26/06	AstraZeneca : Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy	PU